Retinopathy of prematurity (ROP) is a leading cause of childhood blindness worldwide. Although laser photocoagulation remains the gold standard for treating threshold and prethreshold disease (type 1 ROP), the off-label use of anti-vascular endothelial growth factor (anti-VEGF) therapy to treat ROP is increasing. Benefits include acute regression of ROP, growth of retinal vasculature beyond the demarcation line, lesser degree of myopia and peripheral visual field loss, and avoidance of sedation and intubation required for laser. However, controversies regarding anti-VEGF in this vulnerable population persist including choice of anti-VEGF agent, dosing, systemic absorption, safety, and late recurrence. This review updates recent evidence regarding the use of anti-VEGF therapy in the management of ROP.
R etinopathy of prematurity (ROP) remains one of the leading causes of childhood blindness worldwide. 1 Characterized by retinal ischemia, aberrant angiogenesis, fibrovascular proliferation, and progressive vitreoretinal traction, ROP accounts for 14% of childhood blindness within the United States and greater than 20% in developing nations.
2 Vascular endothelial growth factor (VEGF) is the principal mediator of pathological angiogenesis. 2 The Multicenter Trial of Cryotherapy for ROP (CRYO ROP) established the original criteria for "threshold" ROP requiring treatment and reported an almost 50% reduction in total retinal detachment with cryotherapy treatment to the avascular retina.
3
The Early Treatment for Retinopathy of Prematurity Randomized Trial (ETROP) updated these criteria and demonstrated the efficacy of early laser ablative therapy in ROP (prethreshold). These guidelines serve as the gold standard for screening and treatment protocols today. 4 Laser, though effective, has well documented adverse effects including formation of cataract, vitreous hemorrhage, iris synechiae, constriction of visual field, strabismus, and high myopia. Furthermore, laser therapy requires sedation and intubation of the infant, and there is a delay in response after treatment. The ETROP study reported a 55.2% rate of adverse outcomes when using laser in zone I disease.
5 Additionally in a subset of patients with aggressive posterior ROP (APROP), up to 50% of infants progressed to tractional retinal detachment despite appropriate laser treatment. Thus, investigations continue for more effective, less destructive therapies. The off-label use of anti-VEGF has demonstrated efficacy in treating ROP in several retrospective studies and in 1 prospective, randomized controlled trial. 6 However, questions remain regarding optimal anti-VEGF agent, dosing, recurrence, and immediate and long-term safety. This review updates recent evidence regarding the use of anti-VEGF therapy in ROP.
materials and methods
MEDLINE and PubMed were searched for the terms retinopathy of prematurity, bevacizumab, ranibizumab, aflibercept, and anti-vascular endothelial growth factor. Articles published within the past 10 years in the English language were included. Additionally, reference lists of the included studies were searched manually.
results
Over the past 10 years, over 200 articles have been published regarding the use of anti-VEGF in ROP. Fifty-six percent of pediatric and retinal subspecialists self-reported using anti-VEGF agents in ROP.
7 Considerable controversy exists regarding this off-label use of anti-VEGF agents, and several themes emerge including efficacy, recurrence, comparison with conventional laser therapy, safety profile, and systemic effects.
efficacy of anti-VeGF in roP
Current level II and level III evidence support the use of anti-VEGF therapy in type 1 ROP for inducing regression of ROP and promoting normal retinal vascularization. 6, 8, 9 In 47 eyes with stage 3 disease treated with intravitreal bevacizumab (IVB), Henaine-Berra et al 10 reported fluorescein angiographic (FA) evidence of regression of neovascularization and progression of vascularization toward the periphery. In 41 eyes with stage 3 ROP, Wu et al 11 reported a 90% regression rate after IVB. In the Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity Study (BEAT ROP), the only prospective, randomized trial to date, a total of 286 eyes with zone I-posterior II, stage 3+ disease were randomized to IVB versus conventional laser. The IVB cohort demonstrated significantly decreased recurrence compared with the laser cohort (6% vs 26% 27,28 Laser and intraocular inflammation are known to break down the blood-retinal barrier and allow for increased systemic absorption of anti-VEGF therapy after intravitreal injection.
29 It is not clear whether dosing should be decreased when administering bilateral injections or in eyes with prior laser or inflammation.
Effective dosing of anti-VEGF therapy seems not only to be quantity dependent but also time dependent. There is an optimal window, at the first sign of plus disease or neovascularization but before the formation of extensive fibrovascular membranes, during which anti-VEGF has the best benefit to risk profile. Given in stage 3, plus disease, early APROP, and even early stage 4, IVB and IVR induce regression of ROP.
20 However, when administered in late stage 4 or 5 disease, anti-VEGF may cause contraction of the fibrovascular membranes and posterior hyaloid, thereby worsening tractional retinal detachment.
30,31 A similar phenomena of "crunch" after anti-VEGF therapy is observed in proliferative diabetic retinopathy (PDR) where anti-VEGF therapy may worsen traction on the retina. 29 Although few studies have demonstrated successful regression of stage 4 disease with anti-VEGF monotherapy alone, 20 the best potential clinical application of anti-VEGF therapy in stage 4 and 5 disease may be as an adjunctive surgical tool administered within 1 week before pars plana vitrectomy, which may induce regression of the tunica vasculosa and improve dilation, reduce intraoperative bleeding, and facilitate dissection of membranes and 39 showed no aberrant retinal differentiation or ocular damage after IVB in postmortem eyes. The risk of endophthalmitis, iatrogenic cataract, and rhegmatogenous retinal detachment may be minimized by sterile techniques and adjustment of intravitreal injection technique to direct the needle more posteriorly away from the relatively large crystalline lens, along with injecting 1.5-2 mm posterior to the limbus through the pars plicata to avoid perforating through full thickness retina in eyes where the pars plana has not yet fully developed. 40 Additionally, a smaller, shorter needle is recommended (32 gauge, 3/16 inch). The risk of progression to tractional retinal detachment may be mitigated by careful selection of patients, avoiding those with advanced stage 3 disease with robust fibrovascular membranes or stage 4-5 disease, or by using anti-VEGF in the perioperative setting to facilitate surgical repair.
systemic safety data
One of the most important barriers to widespread anti-VEGF use in ROP is lack of certainty regarding the systemic long-term sequelae of anti-VEGF therapy in neonates. Although 56% of pediatric and retinal subspecialists self-reported having used anti-VEGF agents to treat ROP, 66% of those surveyed reported a lack of certainty in systemic effects.
7 Intravitreal anti-VEGF agents in the most commonly used dosages seem to enter systemic circulation and affect serum VEGF levels. Bevacizumab is detected in serum after intravitreal injection in animal models, 41, 42 and serum VEGF levels decrease after intravitreal anti-VEGF injections in infants.
43, 44 Sato et al 43 demonstrated a negative correlation between IVB dose and serum VEGF levels, and Lee et al 45 showed decreased levels of systemic VEGF were maintained for 7 weeks after IVB. Zhou et al 46 demonstrated decreased levels of VEGF 1 day after IVR; however, in contrast to IVB, VEGF levels returned to preinjection range within 1 week after injection.
It is known that VEGF is necessary for the development of organs; thus, systemic suppression of this cytokine raises concerns of impaired neurodevelopment.
47,48 Paradoxical improvement in both the eyes of patients undergoing unilateral anti-VEGF injection supports the notion that decreased systemic VEGF levels from unilateral injections do have clinically significant downstream effects.
27,28 Additionally, anti-VEGF agents in adults have been associated with hypertension, stroke, and myocardial infaction 49 ; thus, prospective, randomized safety studies in infants are necessary. Rare adverse events have been reported after anti-VEGF injection in ROP including failure of pulmonary maturation, 50 respiratory failure, 6 and rare case reports of thromboembolic events, 51 hepatic dysfunction, 36 upper respiratory infection, 52 and nephropathy.
53
Intravenous bevacizumab has been used widely since 2004 in pediatric oncology [54] [55] [56] [57] [58] and for at least 10 years in ROP. No causal association has been established between anti-VEGF therapy and the adverse events reported in ROP. Phase 1 pharmacokinetic study in pediatric patients with refractory solid tumors suggests a dose up to 15 mg/kg bevacizumab every 2 weeks was well-tolerated.
54 Although many point to the higher mortality in the BEAT ROP trial in the IVB cohort [5 (6.6%) vs 2 (2.2%)], this study was not adequately powered to report on safety, and at 2.5-year follow-up, mortality was similar among both cohorts (6 vs 7 infants, respectively).
59 Whereas Morin et al 60 reported the odds of severe neurodevelopmental disabilities at 18 months in 125 infants were 3.1 times higher in infants treated with IVB versus laser, Lien et al 61 reported no difference in neurodevelopment outcomes of 61 infants at 2 years of follow-up between anti-VEGF and laser monotherapy cohorts. Thus, the benefits of anti-VEGF therapy must be carefully weighed against potential unknown side effects. Well-designed trials are needed to address the long-term safety profile of anti-VEGF therapy in neonates.
recurrence
Recurrence remains an ever important and challenging topic. The clinical definition of recurrence varies. Additionally, dosing, treatment, zones, stages, and duration of follow-up vary, making direct comparison between series difficult. Recurrence has been defined as reappearance of plus disease, neovascularization, extraretinal fibrovascular proliferation, new ridge after prior initial regression, or progression of disease despite prior treatment. By FA, eyes with peripheral avascularity (eg, persistent retinal ischemia greater than 2 disc diameters from the ora after intravitreal anti-VEGF treatment) and leakage at the peripheral vascular-avascular junction have been described as "treatment-requiring" to prevent retinal detachment.
62 By convention, most studies generally define recurrence as treatment-requiring progression of disease after prior improvement.
In 317 infants, the ETROP reported that 13.9% needed retreatment after laser therapy. 4 Hwang et al 63 showed, in 54 eyes with type 1 ROP, 3% recurrence after laser [2.6 weeks after treatment, postmenstrual age (PMA) 35.3 weeks] compared with 14% recurrence after IVB (9 weeks after treatment, PMA 45 weeks).
Mueller et al
64 showed, in 54 infants with type 1 ROP, no recurrence in the laser cohort compared with 12% recurrence after IVB (12.7 weeks after treatment). Karkhaneh et al 65 showed, in 86 eyes with zone II, stage 2-3+ ROP, 1.4% recurrence after laser (3 weeks after treatment) compared with 10.5% recurrence after IVB (5 weeks after treatment). Zhang et al 66 showed, in 100 eyes with zone II, stage 2 or 3+ disease, 4% recurrence after laser compared with 52% recurrence after IVR. Thus, it can be inferred that recurrence after laser therapy is observed in a small but significant percentage of patients and generally occurs within the first 9 weeks after treatment.
67
In comparison with conventional laser ablative therapy, recurrence after IVB is observed more frequently and later after initial treatment. Yetik et al 15 showed, in 122 patients with prethreshold, threshold, and APROP disease treated with IVB monotherapy, 4.6% required additional injections by 89 weeks PMA. In the original BEAT ROP study, time to recurrence was 19.2 weeks after IVB compared with 6.4 weeks after laser treatment in zone I. 6 In a follow-up study, 72,73 Thus, though both laser and anti-VEGF therapy induce initial regression of ROP, eyes treated with IVB require longer follow-up for recurrence.
In comparison with IVB and conventional laser ablative therapy, recurrence after IVR is observed more frequently than either IVB or laser and earlier after treatment than IVB. Li et al 74 demonstrated, in 32 eyes treated with IVR monotherapy for APROP, 22% recurrence at 2-8 weeks after injection. Erol et al 53 showed, in 36 eyes with type 1 ROP, 27% of eyes treated with IVR monotherapy recurred at a mean of 41 weeks PMA. Sukgen et al 75 showed, in 90 eyes with severe zone I-posterior II ROP, 27% recurrence after IVB (8.5 weeks after treatment, 43 weeks PMA) and 61% recurrence after intravenous lipid (7.5 weeks after treatment, 43 weeks PMA). Lyu et al 76 showed a 64% recurrence in 50 eyes with type 1 ROP after IVR monotherapy at a mean of 7.9 weeks after treatment. The higher frequency of recurrence after IVR may be related to its shorter half-life 44 and is an important consideration when balancing IVR's shorter duration of systemic VEGF level suppression with its need for frequent follow-up and retreatment.
Recurrence after the combination of laser and anti-VEGF agents as primary treatment has not been extensively studied.
Kim et al
24 demonstrated no recurrence at a mean of 83.6 weeks PMA with a combination of IVB and laser in 18 eyes with zone I ROP. A case of later recurrence after combined IVR and laser treatment in 1 patient with zone I, stage 3+ disease was reported at 4 months after treatment.
77 Regardless of treatment modality, patients with initial regression of ROP should be monitored closely for recurrence, with laser expected to recur earlier and IVR and IVB expected to recur more frequently and later.
Comparison among anti-VeGF agents
Both bevacizumab and ranibizumab lower intraocular and systemic VEGF levels 43, 44 and are effective in inducing acute regression of ROP. However, their individual profiles and sequelae differ. Bevacizumab (Avastin; Genentech Inc, San Francisco, CA) is a 140 kilodalton (kD) full-length antibody, originally approved by the US Food and Drug Administration for metastatic colorectal cancer in 2004. Bevacizumab in combination with chemotherapy has been used extensively in pediatric oncology, [54] [55] [56] [57] [58] and doses up to 15 mg/kg every 2 weeks have been well tolerated in pediatric patients.
54 It has been used off-label extensively in a wide variety of adult chorioretinal disorders including choroidal neovascular membranes, exudative macular degeneration, diabetic retinopathy, and retinal vein occlusions, and of all the anti-VEGF agents, IVB is the most commonly used in ROP. Proponents of IVB cite its extensive use within the ROP population over the past 10 years with few reported adverse events, significant cost benefit (single dose Medicare reimbursement per IVB dose of $64.42 compared with $1986.29 per IVR dose), 78 and fewer recurrences in ROP compared with IVR.
Ranibizumab (Lucentis; Genentech Inc, San Francisco, CA/ Novartis Ophthalmics, Basel, Switzerland) is a 49 kD antigen binding fragment, making it approximately one third the size of bevacizumab. Theoretically, a smaller molecule may allow better tissue penetration; however, in adults being treated for age-related macular degeneration, no difference in treatment efficacy was detected between IVB and IVR (CATT and IVAN trials) . 79, 80 Similarly, in a series of 72 eyes treated with either IVB or IVR monotherapy for zone I-II, stage 3+ ROP, no significant difference in outcomes was observed between IVB and IVR.
18 Although it may not change efficacy, the smaller size of IVR facilitates faster clearance systemically and affords ranibizumab a significantly shorter half-life in serum of 2 hours (compared with the 20 day half-life of bevacizumab).
44
This shorter half-life gives IVR the advantage of shorter duration of systemic VEGF level suppression, which is an important consideration for those with concerns about the systemic sequelae of anti-VEGF therapy in neonates. One potential drawback of its shorter half-life is that IVR shows more recurrence of retinopathy when compared with IVB. 28, 53, 75 Whether this means that IVR should not be used for ROP or simply that IVR should be dosed more frequently has not been elucidated. With repetitive dosing, IVB has been shown to be effective in treating ROP as monotherapy.
15 The Ranibizumab Compared With Laser for the Treatment of Infants Born Prematurely With Retinopathy of Prematurity (RAINBOW) trial has closed recruitment and will evaluate outcomes in ROP treated with IVR compared with laser therapy. 81 There does not seem to be a difference between the axial length and refractive error of eyes at 1 year after treatment with IVB or IVR. 82 No clear safety benefit between either agent has been established.
Comparison to traditional therapy
Level II and III evidence show that anti-VEGF is as effective as laser for acute regression of ROP. Proponents of anti-VEGF therapy cite the demonstrated efficacy of anti-VEGF agents, rapid involution of neovascularization within 48 hours of treatment (compared with 1-8 weeks after laser 63, 64 ), high rate of adverse effects when using laser in zone I, 5 high recurrence in eyes treated with laser for zone I-II, stage 3+ disease, 6 reduction in laser-related constriction of visual field, high myopia, and lack of need for sedation and intubation. The disadvantages of anti-VEGF therapy compared with laser include higher rate of recurrence, longer follow-up required, persistent avascularity noted in the peripheral retina in eyes with regressed ROP, 83 rare adverse events associated with anti-VEGF therapy, and lack of well-conducted safety trials.
Anti-VEGF therapy offers a distinct advantage for zone I and APROP. In the ETROP trial, 30.8% of eyes treated with laser in zone I had unfavorable outcomes. 4 In the BEAT ROP trial, 52.9% of eyes progressed to macular dragging or retinal detachment after laser alone, compared with 3% after IVB. 6 Lepore et al 83 demonstrated, in 24 eyes with zone I, type 1 ROP randomized to laser versus IVB, 17% of eyes treated with laser progressed to retinal detachment after treatment, whereas no progression was observed in the IVB cohort.
disCussion and imPliCations For PraCtiCe screening
The 2013 joint policy statement by the American Academy of Pediatrics, American Academy of Ophthalmology, and American Association for Pediatric Ophthalmology and Strabismus recommends ROP screening for all infants with birth weights of 1500 g or less or gestational age (GA) of 30 weeks or less, or infants with birth weights between 1500 and 2000 g or a GA of more than 30 weeks whose clinical course places them at increased risk for ROP.
84 The International Classification of Retinopathy of Prematurity Revisited 85 is used to classify findings and dictate follow-up schedule.
treatment
Based on the ETROP findings, peripheral ablation is recommended in the presence of plus disease in zones I or II, or stage 3 without plus disease in zone I, also known as type 1 ROP.
5 Based on the BEAT ROP data, IVB may be considered for infants with zone I or posterior zone II early stage 3+ ROP, but a detailed informed consent including safety concerns and the off-label use of bevacizumab must be obtained.
6 Eyes with APROP, vitreous hemorrhage, retinal hemorrhage, inadequate view precluding laser, or progression despite adequate laser therapy may also be considered for IVB. The dose used at our institution is 0.625 mg bevacizumab in 0.05 mL. Given the self-limited nature of ROP and the extended duration of therapeutic concentration of IVB in the vitreous, 86 many eyes require only 1 treatment with IVB. However, eyes treated with IVB require longer follow-up, as recurrence of ROP after IVB occurs later than after laser therapy (16 weeks vs 6.2 weeks after treatment 6 ). At our institution, we typically follow eyes until at least 80 weeks PMA before decreasing the follow-up interval. Families are counseled regarding the off-label use of bevacizumab, the risk of late recurrence, and the importance of lifelong follow-up. In cases of regressed ROP after IVB with unreliable follow-up, or in cases with angiographic evidence of persistent leakage and neovascularization at the vascular-avascular junction, we perform supplementary laser therapy guided by FA to the ischemic retina and skip areas (if present) before discharge. Other physicians report applying zone I-sparing laser therapy empirically to anterior avascular retina at the same time as IVB. 24 In stage 4 or 5 and advanced stage 3+ with extensive fibrovascular membranes, the risk of worsening ROP through the contraction of the posterior hyaloid and fibrovascular membranes after anti-VEGF is higher 87 ; thus, IVB may be considered as salvage therapy in combination with vitrectomy to aid in iris dilation, clearing of media, and decreased intraoperative bleeding to facilitate surgical repair.
areas For Future researCh and ConClusions
With the advancement of neonatal care and the ability to save smaller and more premature infants, ROP remains an ever relevant and challenging disease. Laser therapy has proven effective with low rates of recurrence, but known adverse effects and low rates of success with APROP and zone I disease are noted. Anti-VEGF therapy has proven effective in inducing acute regression of ROP, but concerns regarding safety, dosing, and recurrence remain. The search for effective, less destructive novel therapies continues to evolve, and pegabtanib, 88 insulin-like growth factor, 89 propranolol, 90 peptides, 91 and omega-3 fatty acids 92 have all demonstrated efficacy in small series. Additionally, the role of telemedicine in remote screening continues to develop to allow more effective screening in areas with poor access to ophthalmic care. 93 Further 19.
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